Katherine Piculell

Katherine Piculell

Auto-generated profile, based on publicly available information

Katherine Piculell

Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ICIsidro Cortes-Ciriano
Isidro Cortes-Ciriano
CSChristopher D. Steele
Christopher D. Steele
KPKatherine Piculell
Katherine Piculell
AAAlyaa Al-Ibraheemi
Alyaa Al-Ibraheemi
VEVanessa Eulo
Vanessa Eulo
DMDavid Miller
David Miller
Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multiregional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy-number aberrations (SCNA). Distinct pathways of tumor evolution are associated with inactivation of PRC2 genes and H3K27 trimethylation (H3K27me3) status. Tumors with H3K27me3 loss evolve through extensive chromosomal losses followed by whole-genome doubling and chromosome 8 amplification, and show lower levels of immune cell infiltration. Retention of H3K27me3 leads to extensive genomic instability, but an immune cell-rich phenotype. Specific SCNAs detected in both tumor samples and cell-free DNA (cfDNA) act as a surrogate for H3K27me3 loss and immune infiltration, and predict prognosis. Significance: MPNST is the most common cause of death and morbidity for individuals with NF1, a relatively common tumor predisposition syndrome. Our results suggest that somatic copy-number and methylation profiling of tumor or cfDNA could serve as a biomarker for early diagnosis and to stratify patients into prognostic and treatment-related subgroups. This article is highlighted in the In This Issue feature, p. 517

25 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
HEHillary Elrick
Hillary Elrick
CSCarolin M. Sauer
Carolin M. Sauer
JVJose Espejo Valle-Inclan
Jose Espejo Valle-Inclan
KTKatherine Trevers
Katherine Trevers
MTMelanie Tanguy
Melanie Tanguy
ICIsidro Cortes-Ciriano
Isidro Cortes-Ciriano
Accurate detection of somatic structural variants (SVs) and copy number aberrations (SCNAs) is critical to inform the diagnosis and treatment of human cancers. Here, we describe SAVANA, a computationally efficient algorithm designed for the joint analysis of somatic SVs, SCNAs, tumour purity and ploidy using long-read sequencing data. SAVANA relies on machine learning to distinguish true somatic SVs from artefacts and provide prediction errors for individual SVs. Using high-depth Illumina and nanopore whole-genome sequencing data for 99 human tumours and matched normal samples, we establish best practices for benchmarking SV detection algorithms across the entire genome in an unbiased and data-driven manner using simulated and sequencing replicates of tumour and matched normal samples. SAVANA shows significantly higher sensitivity, and 9- and 59-times higher specificity than the second and third-best performing algorithms, yielding orders of magnitude fewer false positives in comparison to existing long-read sequencing tools across various clonality levels, genomic regions, SV types and SV sizes. In addition, SAVANA harnesses long-range phasing information to detect somatic SVs and SCNAs at single-haplotype resolution. SVs reported by SAVANA are highly consistent with those detected using short-read sequencing, including complex events causing oncogene amplification and tumour suppressor gene inactivation. In summary, SAVANA enables the application of long-read sequencing to detect SVs and SCNAs reliably in clinical samples.

4 April 2023
Verified
Other
Open access
ICIsidro Cortes-Ciriano
Isidro Cortes-Ciriano
CSChristopher D. Steele
Christopher D. Steele
KPKatherine Piculell
Katherine Piculell
AAAlyaa Al-Ibraheemi
Alyaa Al-Ibraheemi
VEVanessa Eulo
Vanessa Eulo
DMDavid Miller
David Miller
Supplementary Table 1 includes the metadata on all subjects, including basic demographics and medical history. Supplementary Table 2 provides statistics on chrom 8 gene expression among tumors with H3K27me3 loss. Note: no changes have been made to this file since our last resubmission.

4 April 2023
Verified
Other
Open access
ICIsidro Cortes-Ciriano
Isidro Cortes-Ciriano
CSChristopher D. Steele
Christopher D. Steele
KPKatherine Piculell
Katherine Piculell
AAAlyaa Al-Ibraheemi
Alyaa Al-Ibraheemi
VEVanessa Eulo
Vanessa Eulo
DMDavid Miller
David Miller
Supplementary figures provide additional details on the genomic landscape of MPNST and interesting cases within the cohort.

11 December 2025
Verified
Other
Open access
ICIsidro Cortes-Ciriano
Isidro Cortes-Ciriano
CSChristopher D. Steele
Christopher D. Steele
KPKatherine Piculell
Katherine Piculell
AAAlyaa Al-Ibraheemi
Alyaa Al-Ibraheemi
VEVanessa Eulo
Vanessa Eulo
DMDavid Miller
David Miller
Supplementary Table 1 includes the metadata on all subjects, including basic demographics and medical history. Supplementary Table 2 provides statistics on chrom 8 gene expression among tumors with H3K27me3 loss. Note: no changes have been made to this file since our last resubmission.

4 April 2023
Verified
Other
Open access
ICIsidro Cortes-Ciriano
Isidro Cortes-Ciriano
CSChristopher D. Steele
Christopher D. Steele
KPKatherine Piculell
Katherine Piculell
AAAlyaa Al-Ibraheemi
Alyaa Al-Ibraheemi
VEVanessa Eulo
Vanessa Eulo
DMDavid Miller
David Miller
Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma, occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and multiregional exome sequencing, transcriptomic, and methylation profiling of 95 tumor samples revealed the order of genomic events in tumor evolution. Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy-number aberrations (SCNA). Distinct pathways of tumor evolution are associated with inactivation of PRC2 genes and H3K27 trimethylation (H3K27me3) status. Tumors with H3K27me3 loss evolve through extensive chromosomal losses followed by whole-genome doubling and chromosome 8 amplification, and show lower levels of immune cell infiltration. Retention of H3K27me3 leads to extensive genomic instability, but an immune cell-rich phenotype. Specific SCNAs detected in both tumor samples and cell-free DNA (cfDNA) act as a surrogate for H3K27me3 loss and immune infiltration, and predict prognosis.Significance:MPNST is the most common cause of death and morbidity for individuals with NF1, a relatively common tumor predisposition syndrome. Our results suggest that somatic copy-number and methylation profiling of tumor or cfDNA could serve as a biomarker for early diagnosis and to stratify patients into prognostic and treatment-related subgroups.This article is highlighted in the In This Issue feature, p. 517